Patents by Inventor Eng Eong Ooi
Eng Eong Ooi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11865083Abstract: The present invention relates to a method of generating a live attenuated vaccine. The present invention also relates to a live attenuated vaccine produced according to the method of the invention.Type: GrantFiled: February 26, 2021Date of Patent: January 9, 2024Assignee: NATIONAL UNIVERSITY OF SINGAPOREInventors: Eng Eong Ooi, Kenneth Goh, Swee Sen Kwek, Choon Kit Tang
-
Publication number: 20230355602Abstract: A method of treating or preventing a viral infection comprising administering a DHODH inhibitor to a patient in need thereof. Also provided is the use of the DHODH inhibitor for the treatment or prevention of a viral infection, alone or in combination with another therapy, and formulations or compositions comprising the DHODH inhibitor suitable for treating or preventing viral infections.Type: ApplicationFiled: August 30, 2021Publication date: November 9, 2023Inventors: Bertil LINDMARK, Mark MCHALE, Ann Gee Lisa OOI, Qihui SEET, Eng Eong OOI
-
Patent number: 11267873Abstract: Isolated monoclonal antibodies which bind to Zika virus envelope protein and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.Type: GrantFiled: October 13, 2017Date of Patent: March 8, 2022Assignees: Massachusetts Institute of Technology, National University of SingaporeInventors: Ram Sasisekharan, Kannan Tharakaraman, Kuan Rong Chan, Satoru Watanabe, Subhash G. Vasudevan, Eng Eong Ooi
-
Patent number: 11219616Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.Type: GrantFiled: December 23, 2019Date of Patent: January 11, 2022Assignees: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
-
Publication number: 20210187094Abstract: The present invention relates to a method of generating a live attenuated vaccine. The present invention also relates to a live attenuated vaccine produced according to the method of the invention.Type: ApplicationFiled: February 26, 2021Publication date: June 24, 2021Applicant: NATIONAL UNIVERSITY OF SINGAPOREInventors: Eng Eong OOI, Kenneth GOH, Swee Sen KWEK, Choon Kit TANG
-
Patent number: 11000516Abstract: Methods of preventing a disease resulting from a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I); a compound of Formula (I) can be first administered to an asymptomatic human subject followed by subsequent doses administered at least once daily. The methods of the invention can be used to prevent a disease resulting from primary and secondary DENV 1-4 viral infections.Type: GrantFiled: December 9, 2016Date of Patent: May 11, 2021Assignees: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.Inventors: Subhash Vasudevan, Geoffrey S. Dow, Satoru Watanabe, Eng Eong Ooi, Jenny Low, Kitti Wing Ki Chan
-
Publication number: 20210009663Abstract: Isolated monoclonal antibodies which bind to Zika virus envelope protein and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.Type: ApplicationFiled: September 28, 2020Publication date: January 14, 2021Inventors: Ram SASISEKHARAN, Kannan THARAKARAMAN, Kuan Rong CHAN, Satoru WATANABE, Subhash G. VASUDEVAN, Eng Eong OOI
-
Patent number: 10829545Abstract: Isolated monoclonal antibodies which bind to Zika virus envelope protein and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.Type: GrantFiled: October 13, 2017Date of Patent: November 10, 2020Assignees: Massachusetts Institute of Technology, National University of SingaporeInventors: Ram Sasisekharan, Kannan Tharakaraman, Kuan Rong Chan, Satoru Watanabe, Subhash G. Vasudevan, Eng Eong Ooi
-
Publication number: 20200338050Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.Type: ApplicationFiled: December 23, 2019Publication date: October 29, 2020Applicants: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
-
Patent number: 10517854Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV 1-4 viral infections.Type: GrantFiled: September 18, 2017Date of Patent: December 31, 2019Assignees: 60 Degrees Pharmaceuticals LLC, National University of Singapore, Singapore Health Services PTE Ltd.Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
-
Publication number: 20190315838Abstract: Isolated monoclonal antibodies which bind to Zika virus envelope protein and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.Type: ApplicationFiled: October 13, 2017Publication date: October 17, 2019Inventors: Ram SASISEKHARAN, Kannan THARAKARAMAN, Kuan Rong CHAN, Satoru WATANABE, Subhash G. VASUDEVAN, Eng Eong OOI
-
Publication number: 20190125855Abstract: The present invention relates to a method of generating a live attenuated vaccine. The present invention also relates to a live attenuated vaccine produced according to the method of the invention.Type: ApplicationFiled: April 13, 2017Publication date: May 2, 2019Applicant: NATIONAL UNIVERSITY OF SINGAPOREInventors: Eng Eong OOI, Kenneth GOH, Swee Sen KWEK, Choon Kit TANG
-
Publication number: 20180360809Abstract: Methods of preventing a disease resulting from a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I); a compound of Formula (I) can be first administered to an asymptomatic human subject followed by subsequent doses administered at least once daily. The methods of the invention can be used to prevent a disease resulting from primary and secondary DENV 1-4 viral infections.Type: ApplicationFiled: December 9, 2016Publication date: December 20, 2018Applicants: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.Inventors: Subhash Vasudevan, Geoffrey S. Dow, Satoru Watanabe, Eng Eong Ooi, Jenny Low, Kitti Wing Ki Chan
-
Publication number: 20180105583Abstract: Isolated monoclonal antibodies which bind to Zika virus envelope protein and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.Type: ApplicationFiled: October 13, 2017Publication date: April 19, 2018Inventors: Ram SASISEKHARAN, Kannan THARAKARAMAN, Kuan Rong CHAN, Satoru WATANABE, Subhash G. VASUDEVAN, Eng Eong OOI
-
Publication number: 20180064693Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I):A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV-4 viral infections.Type: ApplicationFiled: September 18, 2017Publication date: March 8, 2018Applicants: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong OOI, Jenny Low
-
Patent number: 9763921Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.Type: GrantFiled: March 14, 2014Date of Patent: September 19, 2017Assignees: 60 Degrees Pharmaceuticals LLC, Singapore Health Services PTE LTD, National University Of SingaporeInventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
-
Publication number: 20160030403Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.Type: ApplicationFiled: March 14, 2014Publication date: February 4, 2016Applicants: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.Inventors: Geoffrey S. DOW, Subhash VASUDEVAN, Mark REID, Glynn MORRISH, Cynthia SUNG, Abhay RATHORE, Satoru WATANABE, Eng Eong OOI, Jenny LOW
-
Publication number: 20150275295Abstract: The invention concerns a novel parallel method for detecting biological material, in particular peptides or proteins, in a sample at least one probe for use in the said method, a plurality, or library, of said probes for use in said method, and a kit of parts for carrying out said method wherein said probe comprises a binding partner that is specific for said peptide or protein and, attached thereto, an oligonucleotide comprising: i) a first sequence that is complementary to a forward primer sequence for amplification of said oligonucleotide; ii) a second sequence that is complementary to a reverse primer sequence for amplification of said oligonucleotide; and iii) positioned between said first and second sequences an identification sequence of nucleotides or barcode.Type: ApplicationFiled: October 22, 2013Publication date: October 1, 2015Inventors: Linfa Wang, Eng Eong Ooi, October Michael Sessions, Danielle Elizabeth Anderson
-
Publication number: 20100150941Abstract: Passive antibody therapy as a tool for both prophylaxis against—and treatment of—highly pathogenic H5N1 influenza virus, providing immediate immunity is described. It is provided by an antibody specific to hemagglutinin capable of neutralizing influenza viruses and methods of making and using the same, the methods and compounds described herein may be used in diagnostic, prophylactic and therapeutic methods.Type: ApplicationFiled: September 13, 2007Publication date: June 17, 2010Applicants: DSO National Laboratories, St. Jude Children's Research HospitalInventors: Brendon J. Hanson, Angeline P. Lim, Eng Eong Ooi, Adrianus C.M. Boon, Richard J. Webby